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Background: Gefitinib and erlotinib, small-molecule kinase inhibi-
tors that block epidermal growth factor receptor (EGFR) signaling, 
have demonstrated a dramatic response rate and prolonged progres-
sion-free survival (PFS) in patients harboring an activating EGFR 
mutation. We compared the clinical outcomes in gefitinib- and erlo-
tinib-treated patients harboring EGFR mutations who had recurrent 
or metastatic non–small-cell lung cancer (NSCLC).
Methods: A total of 375 patients with recurrent or metastatic 
stage IIIB/IV NSCLC, who had either exon 19 deletion or the 
L858R mutation in exon 21, and had received either gefitinib 
(n = 228) or erlotinib (n = 147), were included in the study. A 
matched-pair case-control study design was implemented in the 
analysis, where 121 pairs of gefitinib-treated and erlotinib-treated 
patients were matched according to sex, smoking history, Eastern 
Cooperative Oncology Group performance status, and types of 
EGFR mutation.
Results: The median age of all patients was 58 years (range, 30–84), 
and more than half of patients had never been smokers (63.6%). Most 
patients had adenocarcinoma (98.3%) and good Eastern Cooperative 
Oncology Group performance status (0, 1) (90.9%). The median 
number of cycles of EGFR tyrosine kinase inhibitor (TKI) treatment 
was 12.7 in the gefitinib group and 10.8 in the erlotinib group. Of the 
242 patients, 63 (26%) received EGFR TKI as first-line therapy. The 
overall response rates and disease control rates in the gefitinib- or 
erlotinib-treated groups were 76.9% versus 74.4% (p = 0.575) and 
90.1% versus 86.8%, respectively (p = 0.305). There was no statisti-
cally significant difference with regard to PFS (median, 11.7 versus 
9.6; p = 0.056) between the gefitinib- and erlotinib-treated groups. 
For patients receiving EGFR TKI as the first-line treatment, there was 
no significant difference between the two treatment groups in overall 
response rates (76.7% and 90.0%) (p = 0.431) and median PFS (11.7 
versus 14.5 months) (p = 0.507).
Conclusion: In NSCLC patients harboring EGFR mutation, treat-
ment with gefitinib and erlotinib resulted in similar effectiveness.
Key Words: Non–small-cell lung cancer, Gefitinib, Erlotinib, 
Epidermal growth factor receptor mutation.
(J Thorac Oncol. 2014;9: 506–511)
Somatic mutations in the epidermal growth factor recep-tor (EGFR) gene have been associated with sensitivity 
to EGFR tyrosine kinase inhibitors (TKIs) in non–small-cell 
lung cancer (NSCLC). Gefitinib and erlotinib are commonly 
used in metastatic NSCLC patients with EGFR mutations.1
Gefitinib yielded an 18.4% objective tumor response and 
a 40.3% symptom improvement rate in randomized phase II tri-
als conducted in a broad spectrum of patients being treated for 
advanced NSCLC.2 However, the IRESSA Survival Evaluation 
in Lung Cancer phase III study showed no significant improve-
ment in median survival with gefitinib in the overall population 
of refractory NSCLC patients.3 Subsequent preplanned subset 
analysis from IRESSA Survival Evaluation in Lung Cancer 
which included never-smoking patients from Asia only showed 
a significant survival benefit compared with placebo.4
Gefitinib, as a first-line therapy in NSCLC, demon-
strated significantly superior outcomes in progression-free 
survival (PFS) compared with carboplatin plus paclitaxel 
within a cohort of East Asian NSCLC patients who had 
never smoked or were former light smokers.5 A preplanned 
biomarker study showed a significant prolongation of PFS in 
the gefitinib group compared with the chemotherapy group 
among EGFR-mutant NSCLC patients. In contrast, gefitinib 
treatment resulted in worse outcomes in patients with wild-
type EGFR. Several randomized phase III studies reported 
consistent improvement in PFS in NSCLC patients with an 
EFGR mutation who were treated with gefitinib compared 
with those with combination chemotherapy.6,7 The response 
rate and PFS of gefitinib in these studies ranged from 62.1% 
to 73.7% and from 9.2 to 10.7 months, respectively.
Similarly, erlotinib has been studied as a first-line therapy 
and in combination chemotherapy in EGFR-mutant NSCLC 
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patients.8 OPTIMAL trial (Erlotinib versus chemotherapy as 
first-line treatment for patients with advanced EGFR muta-
tion–positive NSCLC: multicenter, open-label, randomized 
phase III study),9 a study conducted in China comparing erlo-
tinib and platinum doublet treatment in EGFR-mutant NSCLC 
patients, demonstrated significantly longer PFS with erlotinib 
treatment. Another phase III trial comparing erlotinib versus 
standard chemotherapy as a first-line treatment for European 
patients with advanced EGFR mutation–positive NSCLC also 
reported erlotinib to result in significantly longer PFS. The 
PFS was 13.1 months in the OPTIMAL study compared with 
9.7 months of PFS in the EURTAC study (Erlotinib versus 
standard chemotherapy as first-line treatment for European 
patients with advanced EGFR mutation–positive NSCLC: a 
multicenter, open-label, randomized phase III study).10
Although both agents have similar structures and exem-
plify similar efficacy, there is a paucity of comparative data on 
the efficacy and safety of gefitinib and erlotinib in advanced 
NSCLC patients with EGFR mutation. Previously, we have 
reported that two agents showed similar outcomes in terms of 
response rate, disease control rate, PFS, and overall survival 
(OS) in unselected patients with advanced NSCLC in whom 
prior platinum-based chemotherapy was failed.11 Another pro-
spective, randomized phase II study demonstrated that both 
TKIs were effective in antitumor activity with similar toler-
able toxicity profiles as second-line treatment for a clinically 
selected population of NSCLC.12
The present study sought to compare the clinical out-
comes of gefitinib-treated and erlotinib-treated patients with 
advanced/metastatic or recurrent NSCLC harboring an EGFR 
mutation in either exon 19 or 21.
MATERIALS AND METHODS
Study Population
We retrospectively reviewed medical records of 375 
NSCLC patients (>18 years) who had either exon 19 dele-
tion or L858R mutation on exon 21 and had received gefi-
tinib (n = 228) or erlotinib (n = 147) therapy at Samsung 
Medical Center, Seoul, Korea, between August 2007 and 
December 2011. A matched-pair case-control study design 
aimed to minimize bias was used to analyze 375 patients 
who were consecutively selected to account for significant 
variables such as sex, smoking history, Eastern Cooperative 
Oncology Group performance status (ECOG PS), and 
EGFR mutation types.
All patients had clinically proven recurrent or 
advanced/metastatic stage IIIB/IV NSCLC and EGFR muta-
tions confirmed by DNA-directed sequencing. Patients with 
brain metastasis who underwent whole-brain radiotherapy or 
stereotactic radiosurgery were not excluded from this study. 
The gefitinib group was defined as patients who had been 
treated with gefitinib as first-line treatment or those who had 
received it as second- or higher-line treatment after failure of 
cytotoxic chemotherapy and had not been treated previously 
with erlotinib. The erlotinib group was defined as patients 
who had never been treated with gefitinib but were treated 
with erlotinib as first-line treatment or as second- or higher-
line treatment after failure of prior cytotoxic chemotherapy. 
Clinical parameters collected at the time of EGFR TKI treat-
ment were as follows: age, sex, smoking status, ECOG PS, 
prior systemic chemotherapy regimens, stage, surgery, and 
sites of metastasis. None of the patients received any con-
current chemotherapy or other experimental agents during 
gefitinib or erlotinib treatment. Gefitinib was administered 
daily at a dose of 250 mg/day orally and erlotinib at a dose of 
150 mg/day orally, and the cycle was repeated every 28 days. 
Treatment continued until progressive disease, unacceptable 
toxicity, or patient refusal. Response was assessed according 
to the Response Evaluation Criteria in Solid Tumors guide-
lines,13 and evaluation was performed by dynamic, contrast-
enhanced computed tomography every 8 weeks of EGFR 
TKI treatment.
In total, 121 pairs of gefitinib- or erlotinib-treated 
patients were matched using random number tables accord-
ing to sex (men versus women), smoking history (never ver-
sus ever/current), ECOG PS (0–1 versus ≥2), and the type of 
EGFR mutation (exon 19 deletion versus L858R point muta-
tion). This study was approved by the e-Institutional Review 
Board of Samsung Medical Center.
EGFR Mutation Analysis
Tumor samples for each patient in this study were 
obtained via either diagnostic or surgical procedures. Ninety-
nine patients among the total 375 patients underwent a sec-
ond tissue biopsy to reassess whether an EGFR mutation was 
present. Four patients initially documented as having wild-
type EGFR gene were determined to have an EGFR mutation 
after the second biopsy suggesting the disease had progressed 
since the systemic chemotherapy. Samples consisted of either 
fresh-frozen tumor specimens or paraffin-embedded material. 
Exons 18 to 21 were amplified by polymerase chain reaction 
and analyzed by direct sequencing to detect somatic mutations 
in the EGFR gene.
Statistical Analysis
Treatment outcomes included response rate, disease 
control rate, PFS, and OS. Tumor response to EGFR TKI was 
assessed based on the Response Evaluation Criteria in Solid 
Tumors 1.1. OS was calculated from the time of EGFR TKI 
treatment to the date of death resulting from any cause. PFS 
was defined as the time elapsed between EGFR TKI treatment 
and disease progression or death from disease progression. If 
the complete survival time of a patient was unknown or the 
disease did not progress, patients status was assumed with the 
last known survival and/or contact date.
Response and disease control rates were calculated 
using McNemar’s test. PFS and OS were estimated using 
the Kaplan–Meier method. Differences between the groups 
were compared using the Stratified Cox regression model. 
Baseline characteristics were compared between the groups 
by chi-square and Fisher’s exact tests (when there were fewer 
than 5 expected counts in the contingency table). We also 
used McNemar’s test to assess the relationship between the 
EGFR TKI group and each of the potentially influential fac-
tors, except for matching variables. Cox regression analysis 
was used for univariate and multivariate analyses to identify 
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significant prognostic factors for survival in all patients treated 
with EGFR TKI. Tests were two-sided, and p values less than 
0.05 were considered statistically significant.
RESULTS
Patient Characteristics
Two hundred twenty-eight NSCLC patients harbor-
ing EGFR mutation who had been treated with gefitinib 
were identified in our institution between August 2007 and 
December 2011. The number of patients who received erlo-
tinib treatment was less (n = 147) mostly likely due to differ-
ent approval time for the drugs in Korea (gefitinib in 2003 
versus erlotinib in 2006). By using computed random num-
ber tables for the matching selection process, 131 pairs were 
matched with four variables: sex, smoking status, ECOG 
PS, and EGFR mutation. Ten matched pairs were excluded 
because of a double mutant in EGFR (exon 19 deletion with 
missense mutation in exon 20) in one pair and previous expo-
sure to EGFR TKI in nine pairs. As a result, 121 pairs were 
included in the final analysis.
The median age of all patients was 58 years (range, 
30–84) and 26% were 65 years of age or older. Baseline 
characteristics of matched pairs of patients according to four 
variables (sex, smoking history, ECOG PS, and EGFR muta-
tion) are shown in Table 1. The two groups were comparable 
with respect to demographic and disease characteristics. 
Most patients had adenocarcinoma (98.3%), good ECOG 
PS (0–1) (90.9%), and more than half of patients (63.6%) 
never smoked. Approximately 70% of patients were found 
to have exon 19 deletion in the EGFR gene. Of the 242, 63 
(26%) received EGFR TKIs as first-line treatments, whereas 
the remaining 179 (74%) received at least one prior cyto-
toxic chemotherapy before receiving EGFR TKIs. Because 
gefitinib and erlotinib were approved in Korea for the first-
line therapy in 2010 and 2011, respectively, the proportion of 
patients treated with more than one systemic chemotherapy 
before EGFR TKI treatment was higher in the erlotinib group 
(p = 0.001). The most common sites of metastasis in both 
groups at the time of EGFR TKI treatment were lung, fol-
lowed by bone, the central venous system, pleural effusion, 
and the intra-abdominal region.
Efficacy and Clinical Outcomes of EGFR TKIs
The median number of cycles of EGFR TKI treat-
ment was 12.7 (range, 0–41.6; 95% confidence interval [CI], 
12.2–15.7) in the gefitinib group and 10.8 (range, 0–38.0; 
95% CI, 10.9–14.2) in the erlotinib group. The overall response 
rate was 76.9% in the gefitinib group and 74.4% in the erlo-
tinib group (p = 0.575), with no complete response in either 
group. The median PFS from EGFR TKI treatment in the gefi-
tinib and erlotinib group was 11.7 months (95% CI, 9.4–13.9) 
and 9.6 months (95% CI 8.1–11.1), respectively (Fig. 1). 
Although there was a favorable trend in PFS for the gefitinib 
group compared with the erlotinib group, it did not reach 
statistical significance by exploratory analysis (p = 0.056). 
PFS was analyzed in the two groups of patients with respect 
to various clinicopathologic characteristics. Univariate and 
multivariate analyses revealed that ECOG PS of 2 or more, 
nonadenocarcinoma histology, presence of central nervous 
system (CNS) metastasis, and intra-abdominal metasta-
sis were independent risk factors associated with poor PFS 
(Table 2). Here, we defined intra-abdominal metastasis as liver 
and/or adrenal gland, intra-abdominal lymph nodes, kidney, 
pancreas metastasis. Among 24 patients with intra-abdominal 
metastasis, the number of patients with liver metastasis was 15 
and adrenal gland metastasis was found in 10 patients. Intra-
abdominal lymph nodes, kidney, or pancreas metastasis was 
found in a few cases, thus we included them as intra-abdomi-
nal metastasis category. And a previously reported study also 












(N = 121) 
(%) p
Age
 Median (range) 58 (29–85) 58 (30–84)
 ≥65 64 32 (26.4) 32 (26.4) NA
 <65 178 89 (73.6) 89 (73.6)
Sex
 Men 106 53 (43.8) 53 (43.8) NA
 Women 136 68 (56.2) 68 (56.2)
ECOG PS
 0–1 220 110 (90.9) 110 (90.9) NA
 ≥2 22 11 (9.1) 11 (9.1)
EGFR mutation
 Exon 19 deletion 170 85 (70.2) 85 (70.2) NA
 L858R mutation 72 36 (29.8) 36 (29.8)
Histology
 Adenocarcinoma 236 119 (98.3) 117 (96.7) 0.408
 Nonadenocarcinoma 6 2 (1.7) 4 (3.3)
No. of prior systemic chemotherapy
 0 63 43 (35.5) 20 (16.5) 0.001
 1 147 65 (53.7) 82 (67.8)
 ≥2 32 13 (10.7) 19 (15.7)
Smoking
 Never 154 77 (63.6) 77 (63.6) NA
 Current or ever 88 44 (36.4) 44 (36.4)
Stage of disease
 IIIB 3 1 (0.8) 2 (1.7) NA
 IV 178 90 (74.4) 88 (72.7)
 Recurred 61 30 (24.8) 31 (25.6)
Metastasized region
 CNS 70 33 (27.7) 37 (30.6) 0.628
 Lung to lung 99 46 (38.0) 53 (49.5) 0.36
 Pleural effusion 73 39 (32.2) 34 (28.1) 0.484
 Intra-abdominal 24 11 (9.1) 13 (10.7) 0.667
 Bone 83 46 (38.0) 37 (30.8) 0.241
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, 
epidermal growth factor receptor; NA, not applicable; CNS, central nervous system.
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was correlated with poor prognosis in NSCLC patients treated 
with erlotinib as salvage therapy.14
In univariate analysis, patients treated with EGFR TKI 
as first-line treatment seemed to have a longer PFS than those 
with prior cytotoxic chemotherapy before EGFR TKI treat-
ment. However, longer PFS trend associated with first-line 
EGFR TKI treatment was diminished in then multivariate 
analysis (hazard ratio, 1.32; 95% CI 0.92–1.88; p = 0.135).
First-Line EGFR TKIs
For subgroup analysis, 63 patients (26%) treated with 
first-line EGFR TKIs were analyzed with regard to response 
rate, PFS, and OS in both groups. The response rates in 
the gefitinib- and erlotinib-treated groups were 76.7% and 
90.0%, respectively (p = 0.431). There was no significant 
difference between the two treatment groups in median PFS 
(11.7 months; 95% CI, 6.7–16.7 versus 14.5 months; 95% CI, 
8.7–20.4) (p = 0.507) (Fig. 2). The median OS was 24.5 months 
(95% CI, 8.6–40.4) in the gefitinib group, whereas in the erlo-
tinib group, the median OS had not been reached at the time 
of the analysis. Using univariate and multivariate analyses for 
PFS in patient subgroups, smoking (p = 0.009) and the pres-
ence of CNS metastasis (p = 0.002) were found to be indepen-
dent predictors for poor PFS.
Safety and Dose Adjustment of EGFR TKIs
EGFR TKI treatment was generally well tolerated, and 
only a small number of patients required dose adjustment. 
Twenty-two patients treated with erlotinib required dose 
reduction from 150 to 100 mg/day, whereas one patient with 
gefitinib needed dose reduction from 250 mg once a day to 
250 mg every other day due to grade 3/4 skin rash and diar-
rhea. Neither interstitial lung disease (ILD)-like events nor 
toxic death was observed in either group.
DISCUSSION
In the present matched-pair case-control study, the 
clinical effectiveness of gefitinib and erlotinib was similar 
in selected patients with advanced/metastatic or recurrent 
NSCLC harboring activating EGFR mutation. Brain metasta-
sis is a well-known important prognostic factor for all NSCLC 
as also shown in our study (Table 2). However, in this study, 
EGFR TKIs were treated as first-line or second- or higher-line 
of therapy; therefore, most of the patients were not screened 
for the presence of brain metastasis by brain magnetic reso-
nance imaging at the time of EGFR TKI treatment. Therefore, 
the four matching variables (sex, smoking history, ECOG PS, 
and type of EGFR mutation) which are considered as gener-
ally acceptable variables were selected in this study.
The response rates and disease control rates in the gefi-
tinib- and erlotinib-treated groups in this study were 76.9% 
versus 74.4% (p = 0.575) and 90.1% versus 86.8% (p = 0.305), 
respectively, which are consistent with previous studies.5–7,9 
The response rates and disease control rates of erlotinib were 
reported to be up to 82% and 96%, respectively, in patients 
with NSCLC with EGFR mutations,9 and the response rate 
of gefitinib ranged from 70% to 80%5–7 in EGFR-mutated 
NSCLC patients. A previously reported prospective phase II 
study conducted at our institution also demonstrated12 that 
both gefitinib and erlotinib showed similar antitumor activity 
as second-line treatment for clinically selected patients with-
out known EGFR mutation status.
Until now, comparative studies on gefitinib and erlotinib 
have not been investigated in NSCLC patients positive for 
EGFR mutations. In an Iressa Pan-Asia Study (IPASS) study, 
a subgroup analysis of patients with EGFR mutations demon-
strated that the PFS of patients treated with first-line gefitinib 
was 10.7 months compared with 6 months for those treated with 
chemotherapy.5 The PFSs of gefitinib-treated patients in the 
NEJ002 and WJTOG3405 studies were 10.4 and 9.2 months, 
respectively.6,7 Regarding erlotinib, the PFSs of erlotinib-treated 
patients in OPTIMAL and EURTAC studies were 13.1 and 
9.7 months, respectively.9,10 Indirect comparisons of these two 
EGFR TKIs resulted in inconsistency with regard to PFS.
Statistically, it is very complicated to adjust various 
types of chemotherapy and/or periods of use for each che-
motherapeutic agent, and this issue is difficult to overcome. 
Therefore, the primary endpoint of this study for comparing 
the efficacy of both TKIs is mainly focused on PFS, not on 
OS. In this study, the median PFS in the gefitinib-treated 
group was 11.7 months (95% CI, 9.4–13.9) and 9.6 months 
(95% CI 8.1–11.1) for the erlotinib-treated group. We did 
not find any statistical difference in PFS between the two 
groups. In the subgroup analysis of patients treated with 
EGFR TKIs as a first-line therapy, no significant difference 
in PFS was noted between the two groups (11.7 months for 
gefitinib; 95% CI, 6.7–16.7 versus 14.5 months for erlo-
tinib; 95% CI, 8.7–20.4) (p = 0.507), suggesting that these 
two EGFR TKIs have similar effectiveness in terms of PFS. 
However, due to the small number of first-line EGFR TKI–
treated patients (N = 63), the analysis is limited in deter-
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We also found that the PFS for patients treated with 
EGFR TKI (either gefitinib or erlotinib) as first-line therapy 
was 13.1 months (95% CI 8.7–17.5), compared with 10.1 
months (95% CI, 8.7–11.5) (p = 0.082) for patients who 
received the treatment as a second- or higher-line of therapy. 
Previously, Rosell et al. reported that in a group of 217 EGFR-
mutant NSCLC patients, PFS was similar for patients receiv-
ing first-line (n = 113) (14.0 months; 95% CI, 9.7–18.3) or 
second-line therapy (n = 104) (13.0 months; 95% CI, 9.7–
16.3; p = 0.62). Our results are consistent with this previous 
study, highlighting that EGFR-mutant lung cancer is a distinct 
class of lung cancer, and EGFR TKIs can induce durable and 
high responses irrespective of the line of therapy.15
Given the retrospective nature of this study, toxicity pro-
files were not always complete. However, we observed that 
dose reduction due to adverse events were more frequent in 
the erlotinib-treated group. This result is in line with a pre-
vious study16 in that the plasma concentration of erlotinib is 
higher than that of gefitinib in standard dosage. Nevertheless, 
both drugs were well tolerated, and no treatment-related mor-
tality was found. No occurrence of ILD or an ILD-like event 
was noted in this cohort, confirming that the incidence rate of 
ILD in Korean patients is very rare compared with the rate in 
Japan, where a 3% to 4% incidence rate has been reported.17
To the best of our knowledge, this is the first matched-
pair case-control study in comparing the effectiveness of 
gefitinib and erlotinib in EGFR mutation–positive, advanced 
NSCLC patients. The study however has several limitations. 
Although four important baseline variables with baseline 
characteristics were matched between two groups, the number 
and types of chemotherapy regimens administered before or 
after treatment were varied and were not accounted for. This 
difference may have introduced potential bias, which in turn 
might have affected the study outcomes particularly the PFS 
and OS. The treatment responsiveness was evaluated by con-








HR (95% CI) p
Age
 <65 178 (84) 10.4
 ≥65 64 (26) 9.9 0.509 0.79 (0.55–1.12) 0.785
Sex
 Women 136 (56) 10.7
 Men 106 (44) 9.1 0.176 0.99 (0.65–1.50) 0.953
ECOG PS
 0–1 220 (91) 10.4
 ≥2 22 (9) 7.0 0.007 2.61 (1.53–4.44) 0.001
Smoking
 Never 154 (64) 11.1
 Current or ever 88 (36) 7.8 0.012 1.48 (0.96–2.27) 0.077
EGFR mutation
 Exon 19 deletion 170 (70) 10.6
 L858R mutation 72 (30) 9.2 0.293 1.21 (0.88–1.67) 0.250
Histology
 Adenocarcinoma 236 (98) 10.4
 Nonadenocarcinoma 6 (2) 3.3 0.001 3.62 (1.51–8.69) 0.004
No. of prior systemic chemotherapy
 0 63 (26) 12.9
 ≥1 179 (74) 9.9 0.031 1.32 (0.92–1.88) 0.135
Metastasized region
 CNS 70 (29) 9.5 0.069 1.50 (1.10–2.10) 0.020
 Lung to lung 99 (41) 10.6 0.632 1.07 (0.78–1.48) 0.677
 Pleural effusion 73 (30) 10.7 0.512 1.35 (0.94–1.93) 0.10
 Intra-abdominal 24 (10) 6.9 0.101 1.71 (1.03–2.82) 0.037
 Bone 83 (34) 10.1 0.279 1.04 (0.75–1.44) 0.797
EGFR TKI
 Gefitinib 121 (50) 11.7
 Erlotinib 121 (50) 9.6 0.139 1.14 (0.85–1.52) 0.386
NSCLC, non–small-cell lung cancer; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PFS, progression-free survival; HR, hazard ratio; CI, confidence 
interval; ECOG PS, Eastern Cooperative Oncology Group performance status; CNS, central nervous system.
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TKI in this study. However, brain magnetic resonance imaging 
or bone scan was not routinely checked but was performed 
only when clinically indicated, which may have affected the 
evaluation of PFS. Moreover, due to the retrospective nature 
of the study, other unmeasured confounding factors may have 
been introduced to the treatment groups. Timely and interest-
ingly, a prospective, randomized trial of erlotinib versus gefi-
tinib in advanced NSCLC with exon 21 mutation is currently 
ongoing,18 which may address limitations of the current study 
and further strengthen the growing body of evidence on the 
treatment efficacy of EGFR TKI.
In conclusion, the present study demonstrated that both 
gefitinib and erlotinib are well tolerated and have similar 
effectiveness in NSCLC patients harboring EGFR mutation.
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FIGURE 2.  Kaplan–Meier plots for subgroup analysis. First-
line EGFR TKI treatment. Progression-free survival within the 
treatment groups. EGFR TKI, epidermal growth factor recep-
tor tyrosine kinase inhibitor.
